Akari Therapeutics AKTX Cash Flow Statement (2011-2026)

NASDAQ AKTX
$7.00 -0.66 (-8.62%)
As of: Nov 10, 2026 · 3:08 PM EST
Reported Financials

Akari Therapeutics Quarterly Cash Flow Statement

Periods 44 quarters
Latest Jun 2026

Akari Therapeutics reported cash from operations of -$3.11M and free cash flow of -$3.11M for the quarter ended Jun 2026, up 4.5% year over year. This cash flow statement covers 44 quarters of results from Dec 2011 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Dec2011 Dec2012 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Dec2016 Jun2017 Dec2017 Jun2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Jun2021 Dec2021 Jun2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
0.91M-6.81M-4.35M-5.68M1.00M-4.00M-2.87M-4.14M-5.57M-7.56M-2.90M-3.77M-3.71M-1.90M-6.40M-5.30M-14.46M-4.81M
Depreciation and DepletionDep. & Depletion
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
Depreciation & Amortization (CF)Dep. & Amort.
986.000.00M0.00M0.00M0.00M0.00M0.01M0.00M
Share-based CompensationStock Comp.
0.08M0.08M0.27M0.00M0.31M0.30M0.30M0.45M0.25M1.26M1.02M0.72M0.69M0.47M0.31M0.71M
Deferred Taxes
-0.86M
Gains from Investment SecuritiesGains Investment
-0.10M-0.13M0.23M
Asset Writedowns and ImpairmentWritedown
5.18M8.40M0.03M
Other non-cash itemsOther Non-Cash
-0.28M0.00M0.00M-0.04M-0.02M-0.20M0.26M0.02M-0.16M0.13M-0.03M-0.37M0.97M2.55M-0.02M0.06M
Change in Working Capital
Change in Account PayablesChange Payables
Change in Accrued ExpensesChange Accrued Exp.
-0.75M1.83M-0.32M-0.34M-0.17M-0.10M1.46M1.49M0.93M1.34M0.48M-0.60M-0.70M-0.18M0.93M0.62M
Change in Other Operating AssetsOther Assets Change
-0.33M-0.83M0.24M0.03M-0.05M-0.29M-0.14M-0.56M-0.41M-0.20M-0.08M-0.18M-0.13M-0.20M0.09M-0.19M
Change in Other Operating LiabilitiesOther Liabilities Change
Other Working Capital ChangesOther WC Changes
0.33M0.83M-0.24M-0.03M0.05M0.29M0.14M0.56M0.41M0.20M0.08M0.18M0.13M0.20M-0.09M0.19M
Cash from OperationsCash from Ops.
-0.70M-4.23M-4.88M-4.69M-2.45M-4.41M-4.04M-4.89M-1.49M-2.12M-2.15M-3.26M-2.12M-3.04M-2.49M-3.11M
Investing Activities
Capital ExpendituresCapex
Change in Property, Plant and EquipmentChange in PP&E
Cash from Investing ActivitiesCash from Investing
Financing Activities
Debt Issuance and Repayment
Long-Term Debt IssuancesLT Debt Issuance
Long-Term Debt RepaymentsLT Debt Repayment
Net Long-Term Debt Issued (Repaid)Net LT Debt
Short-Term Debt repaymentsST Debt Repayment
0.22M0.33M0.34M0.22M0.11M0.17M0.17M0.06M0.10M0.16M
Net Short-Term Debt Issued (Repaid)Net ST Debt
-0.22M-0.33M-0.34M-0.22M-0.41M-0.05M-0.03M-0.06M-0.03M-0.05M
Net Debt Issuances and RepaymentsNet Debt Issuance
-0.22M-0.33M-0.34M-0.22M-0.41M-0.05M-0.03M-0.06M-0.03M-0.05M
Change in Capital Stock
Common Stock IssuedStock Issued
5.99M3.21M0.29M3.52M-0.11M3.13M2.65M3.60M5.88M0.19M8.24M
Net Shares Issued and RepurchasedNet Shares Issued
5.99M3.21M0.29M3.52M-0.11M3.13M2.65M3.60M5.88M0.19M8.24M
Net Equity Issued and RepurchasedNet Equity Issued
5.99M3.21M0.29M3.52M-0.11M3.13M2.65M3.60M5.88M0.19M8.24M
Other financing activities (as filed)
-0.19M
Cash from Financing ActivitiesCash from Financing
5.99M3.21M0.29M3.52M1.51M7.76M-0.44M2.15M2.13M3.38M1.90M5.76M0.05M8.04M
Additional items
Exchange Rate EffectFX Effect
0.28M-0.02M0.00M0.01M-0.01M0.00M0.00M0.00M0.00M
Change in Cash
-0.43M1.74M-1.67M-4.40M-2.45M-0.89M-2.54M2.87M-1.93M0.41M-0.02M0.13M-0.23M2.72M-2.44M4.93M
Ending Cash Balance
12.32M14.06M3.79M9.36M8.15M13.25M11.58M7.18M4.73M3.85M1.31M4.18M2.25M2.66M2.64M2.77M2.54M5.26M2.83M7.75M
Free Cash FlowFCF
-0.70M-4.23M-4.88M-4.69M-2.45M-4.41M-4.04M-4.89M-1.49M-2.12M-2.15M-3.26M-2.12M-3.04M-2.49M-3.11M
Net Cash FlowNCF
-0.70M1.76M-1.67M-4.40M-2.45M-0.89M-2.53M2.87M-1.93M0.03M-0.02M0.13M-0.22M2.72M-2.44M4.93M
Interest Paid
0.07M0.02M0.01M0.01M0.09M0.01M0.01M

Akari Therapeutics Cash Flow Statement API

Pull Akari Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=AKTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY